BIO CEO’s closing plenary session featured plenty of crystal ball gazing and candid quips about what 2011 has in store for the biotech industry. While the panel provided an in-depth look at how buy-side and sell-side analysts evaluate the industry, the BIO/IPREO Investor Perception Study reveals that the majority of investors believe biotech is headed in the right direction. Access full study deck here: BIO CEO – IPREO Biotech Investor Perception Study
The study also reveals that a majority of investors believe the industry is undervalued.
Investors also believe that M&A and clinical trial news are the most important catalysts when it comes to moving the sector higher. The study also shows that investors believe 2011 will see more biotech IPOs than 2010. If the spate of biotech and healthcare IPOs of the past two weeks is any indication, their feelings are well-placed.
IPREO conducted the study by gathering feedback from 135 investment professionals representing firms with $2 trillion in equity assets under management, including $166 billion invested in healthcare and $38 billion invested in biotech.
Click here to learn more about IPREO.